[Tract element contents in thymus gland in experimental leukemia].
Explore the source record for details and available documents.
SEARCH · PubMed Health
Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.
Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
It has previously been demonstrated that an in vitro antineoplastic treatment may induce new antigenic specificities in murine lymphomas. L1210 leukemia has been altered by DIC (L1210/DIC); drug-treated L1210 subline has been rejected by syngeneic animals. Here spleen cells from mice, normal or immune to L1210/DIC, have been stimulated in vitro by the L1210/DIC cells as measured by 3-h-thymidine uptake. Spleen cell stimulation did not occur with other syngeneic tumor cells and, as expected, spleen cells have been triggered by allogeneic cells. DIC-induced antigens stimulating syngeneic lymphocytes, as allogeneic cells did, have been demonstrated on L1210/DIC cells.
Sulfoethylated (1 --> 3)-beta-D-glycan (SE-glycan) is a well-known biological response modifier, which activates the immune system via the influence on macrophages and lymphocytes. In these experiments, SE-glycan suppressed the growth of solid transplants of leukemias P-388 and L1210/1 in mice and, when combined with cyclophosphamide, significantly potentiated its action. The administration of SE-glycan allowed the cyclophosphamide dose to be reduced by half without negatively influencing the curative effect. The proposed treatment also led to an increase in the activity of lysosomal proteases (cathepsins B, L and D) in tumor tissues. The extent of changes was in direct relation to the therapeutic effect.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.